Skip to main content

Table 1 Clinical features and histological type of glioma cohort (n = 100)

From: P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas

Age (years)

2–85

Sex

 

 Male

51

 Female

49

Surgery

 

 Biopsy

11

 Resection

89

Presentation

 

 Primary

79

 Recurrence

21

IDH status

 

 IDH-mutant

29

 IDH-wildtype

71

Histologic subtype

 

 Astrocytoma, IDH-mutant, CNS WHO grade 2

3

 Astrocytoma, IDH-mutant, CNS WHO grade 3

12

 Astrocytoma, IDH-mutant, CNS WHO grade 4

5

 Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 2

5

 Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, CNS WHO grade 3

3

 Glioblastoma, IDH-wildtype, CNS WHO grade 4

62

 Pilocytic astrocytoma, CNS WHO grade 1

5

 Low-grade glioneuronal tumor / Pleomorphic Xanthoastrocytoma

1

 Angiocentric glioma, CNS WHO grade 1

1

 Diffuse hemispheric glioma, H3 G34-mutant, CNS WHO grade 4

1

 Diffuse low-grade glioma, MAPK pathway-altered

1

 Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype

1